DiFusion’s CleanFUZE has completed a series of in vivo and in vitro clinical tests, which showed that it could eradicate 99.998% of methicillin-resistant staphylococcus aureus bacteria and prevent biofilm adhesion.
CleanFUZE will be developed using Evonik’s VESTAKEEP PEEK and DiFusion’s silver zeolite based technology.
The new load-bearing medical polymer can also be used to engineer orthopedic or dental implant.
The development of CleanFUZE is also expected to reduce surgical site infections in orthopedics and oral surgery.
DiFusion development vice president Jami Hafiz said, "VESTAKEEP® PEEK’s superior properties in many critical areas are the primary reason we are working with Evonik to develop CleanFUZE.”
Evonik America high-performance polymers business line vice president and general manager Jeff Smith said, "Evonik’s ability to create custom-developed products is essential to meeting the demands of our customers and providing them with solutions to their specific challenges."
DiFusion CEO Derrick Johns said, "Our combined technical knowledge and Evonik’s world-class polymer chemistry will lead to a new class of bioactive medical polymers."